The Apex Times
Above the Noise
Business Wire
BusinessAMD says Instinct AI systems are now operating in Saudi Arabia, highlighting a potential ramp tied to additional data-center powerThe Apex TimesBusinessCostco and Old Navy promotions, Apple leadership change, and other retail and tech themes surfaced in a market roundupThe Apex TimesBusinessDeere named among stocks making notable moves in late-Thursday trading recapThe Apex TimesBusinessSalesforce says AI-driven revenue momentum is building as Agentforce adoption spreadsThe Apex TimesBusinessSalesforce backs HiBob to bolster workforce AI, and adds a new AgentExchange email toolThe Apex TimesBusinessEverPass Media expands NFL distribution via multi-year Netflix deal for 2026 slateThe Apex TimesBusinessUnitedHealth shares rise as it moves to drop prior-authorization checks for about 30% of servicesThe Apex TimesBusinessBerkshire Hathaway CEO Greg Abel to Appear on TV in Rare Interview, With Focus Likely on Insurance and BNSFThe Apex TimesBusinessCoinbase expands Webull crypto trading footprint into CanadaThe Apex TimesBusinessBroadcom leans harder into VMware AI with a push aimed at enterprise rivalsThe Apex TimesBusinessModerna shares jump after GSK advances a rival mRNA flu vaccine to Phase IIIThe Apex TimesBusinessYahoo Finance points to “buy zones” for Microsoft, Palantir, Shopify and ServiceNowThe Apex TimesBusinessAMD says Instinct AI systems are now operating in Saudi Arabia, highlighting a potential ramp tied to additional data-center powerThe Apex TimesBusinessCostco and Old Navy promotions, Apple leadership change, and other retail and tech themes surfaced in a market roundupThe Apex TimesBusinessDeere named among stocks making notable moves in late-Thursday trading recapThe Apex TimesBusinessSalesforce says AI-driven revenue momentum is building as Agentforce adoption spreadsThe Apex TimesBusinessSalesforce backs HiBob to bolster workforce AI, and adds a new AgentExchange email toolThe Apex TimesBusinessEverPass Media expands NFL distribution via multi-year Netflix deal for 2026 slateThe Apex TimesBusinessUnitedHealth shares rise as it moves to drop prior-authorization checks for about 30% of servicesThe Apex TimesBusinessBerkshire Hathaway CEO Greg Abel to Appear on TV in Rare Interview, With Focus Likely on Insurance and BNSFThe Apex TimesBusinessCoinbase expands Webull crypto trading footprint into CanadaThe Apex TimesBusinessBroadcom leans harder into VMware AI with a push aimed at enterprise rivalsThe Apex TimesBusinessModerna shares jump after GSK advances a rival mRNA flu vaccine to Phase IIIThe Apex TimesBusinessYahoo Finance points to “buy zones” for Microsoft, Palantir, Shopify and ServiceNowThe Apex TimesBusinessAMD says Instinct AI systems are now operating in Saudi Arabia, highlighting a potential ramp tied to additional data-center powerThe Apex TimesBusinessCostco and Old Navy promotions, Apple leadership change, and other retail and tech themes surfaced in a market roundupThe Apex TimesBusinessDeere named among stocks making notable moves in late-Thursday trading recapThe Apex TimesBusinessSalesforce says AI-driven revenue momentum is building as Agentforce adoption spreadsThe Apex TimesBusinessSalesforce backs HiBob to bolster workforce AI, and adds a new AgentExchange email toolThe Apex TimesBusinessEverPass Media expands NFL distribution via multi-year Netflix deal for 2026 slateThe Apex TimesBusinessUnitedHealth shares rise as it moves to drop prior-authorization checks for about 30% of servicesThe Apex TimesBusinessBerkshire Hathaway CEO Greg Abel to Appear on TV in Rare Interview, With Focus Likely on Insurance and BNSFThe Apex TimesBusinessCoinbase expands Webull crypto trading footprint into CanadaThe Apex TimesBusinessBroadcom leans harder into VMware AI with a push aimed at enterprise rivalsThe Apex TimesBusinessModerna shares jump after GSK advances a rival mRNA flu vaccine to Phase IIIThe Apex TimesBusinessYahoo Finance points to “buy zones” for Microsoft, Palantir, Shopify and ServiceNowThe Apex TimesBusinessAMD says Instinct AI systems are now operating in Saudi Arabia, highlighting a potential ramp tied to additional data-center powerThe Apex TimesBusinessCostco and Old Navy promotions, Apple leadership change, and other retail and tech themes surfaced in a market roundupThe Apex TimesBusinessDeere named among stocks making notable moves in late-Thursday trading recapThe Apex TimesBusinessSalesforce says AI-driven revenue momentum is building as Agentforce adoption spreadsThe Apex TimesBusinessSalesforce backs HiBob to bolster workforce AI, and adds a new AgentExchange email toolThe Apex TimesBusinessEverPass Media expands NFL distribution via multi-year Netflix deal for 2026 slateThe Apex TimesBusinessUnitedHealth shares rise as it moves to drop prior-authorization checks for about 30% of servicesThe Apex TimesBusinessBerkshire Hathaway CEO Greg Abel to Appear on TV in Rare Interview, With Focus Likely on Insurance and BNSFThe Apex TimesBusinessCoinbase expands Webull crypto trading footprint into CanadaThe Apex TimesBusinessBroadcom leans harder into VMware AI with a push aimed at enterprise rivalsThe Apex TimesBusinessModerna shares jump after GSK advances a rival mRNA flu vaccine to Phase IIIThe Apex TimesBusinessYahoo Finance points to “buy zones” for Microsoft, Palantir, Shopify and ServiceNowThe Apex Times
Back to front
FDA Advisory Committee backs Moderna’s mRNA-1010 with unanimous vote; PDUFA goal date set for Aug. 5, 2026
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 18, 4:05 PM EDT

FDA Advisory Committee backs Moderna’s mRNA-1010 with unanimous vote; PDUFA goal date set for Aug. 5, 2026

A panel of FDA advisers voted unanimously that the benefit-risk profile of Moderna’s investigational seasonal influenza vaccine candidate, mRNA-1010, is favorable, keeping the company on track for an FDA decision targeted for August 2026.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna said the FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of the benefit-risk profile of mRNA-1010, an investigational seasonal influenza vaccine candidate. The vote is a key milestone in the U.S. regulatory process because it informs the FDA’s decision on whether a product’s expected benefits outweigh its risks.

The company said the FDA Prescription Drug User Fee Act (PDUFA) goal date for the review of mRNA-1010 remains August 5, 2026. Under PDUFA, the FDA sets a target date for acting on certain applications, which can include approvals, complete response actions, or other regulatory outcomes.

Moderna’s announcement framed the advisory committee’s decision as support for the benefit-risk profile of the candidate, without detailing any additional committee discussion, vote counts, or specific efficacy and safety findings in the information provided in the report.

mRNA-1010 is described as an investigational seasonal influenza vaccine. Seasonal flu vaccines are intended to protect against circulating influenza strains during the flu season, and mRNA platforms aim to generate immune responses by instructing cells to produce an influenza-related antigen.

Regulatory advisory committee votes can shape timelines and expectations, but they do not replace the FDA’s final determination. Even after a favorable advisory recommendation, the agency can still request additional information or impose label limitations, depending on what it determines from its complete evidence package.

For Moderna, the committee vote underscores ongoing progress as it works through late-stage regulatory steps for its flu franchise. A seasonal influenza vaccine market is large and competitive, and near-term FDA action can affect how investors and partners assess the program’s commercial prospects.

The announcement did not provide additional details in the information provided, including the specific data the committee relied on, any conditions attached to the vote, or whether any committee members expressed reservations. It also did not disclose what, if anything, the FDA may still require ahead of the PDUFA decision date.

What to watch next is whether the FDA’s final decision aligns with the unanimous committee vote by the August 5, 2026 target date, and whether Moderna’s disclosure around the application expands to include more granular safety and effectiveness context as the review advances.

Why It Matters

  • A unanimous advisory committee vote can increase confidence that the FDA will view the benefit-risk balance as acceptable, though the agency still makes the final call.
  • The August 5, 2026 PDUFA goal date sets a concrete near-term regulatory timeline that can influence how markets price the candidate’s probability of approval.
  • For Moderna, a favorable vote advances a high-profile development program in a major seasonal vaccine category where adoption and labeling details matter.
  • The lack of specific efficacy and safety details in the announcement means investors and clinicians will likely look to the FDA review materials and any subsequent Moderna disclosures to assess the evidence more closely.

Sources

Key Facts

  • An FDA advisory committee voted unanimously that the benefit-risk profile of Moderna’s investigational seasonal influenza vaccine candidate mRNA-1010 is favorable.
  • The advisory committee vote was reported by Moderna on June 18, 2026.
  • The FDA PDUFA goal date for the mRNA-1010 review remains August 5, 2026.
  • mRNA-1010 is an investigational seasonal influenza vaccine being reviewed by the FDA.

Healthcare Related

FDA Advisory Committee backs Moderna’s mRNA-1010 with unanimous vote; PDUFA goal date set for Aug. 5, 2026 | The Apex Times